Review Confirms Very Limited Evidence for Cannabinoids in Rheumatic Disease Pain
A systematic review of four trials with just 203 patients found that cannabinoids showed some pain and sleep benefits in rheumatic conditions, but nearly half of patients experienced side effects like dizziness and drowsiness.
Quick Facts
What This Study Found
This review identified the same thin evidence base for cannabinoids in rheumatic diseases: four short studies totaling only 203 patients across rheumatoid arthritis, fibromyalgia, and osteoarthritis.
Cannabinoids had a statistically significant effect on pain in two of the studies and on sleep in two studies. Quality of life improved in one study. However, the osteoarthritis trial was terminated early because the treatment was not working.
The side effect profile was notable. Dizziness, cognitive problems, drowsiness, and nausea were reported by nearly half of patients. No serious adverse events occurred during the short study durations.
Key Numbers
203 total patients across four studies. Pain significant in 2/4 studies. Sleep significant in 2/4 studies. Quality of life improved in 1/4. OA trial terminated for futility. Dizziness, cognitive problems, drowsiness, and nausea in nearly 50% of patients. All three completed studies had high risk of bias.
How They Did This
Systematic search of Medline, Embase, and CENTRAL databases. Included randomized controlled trials comparing cannabinoids (phyto- and synthetic) with any control for rheumatic disease pain. Assessed efficacy (pain, sleep, quality of life), tolerability (dropout rates), and safety (serious adverse events). All three completed studies had high risk of bias.
Why This Research Matters
This review from a different research group confirms the same conclusion as RTHC-01154: the evidence base for cannabinoids in rheumatic pain is extremely thin. The additional detail on side effects (affecting nearly half of patients) and the failed osteoarthritis trial provide important counterweights to the narrative that cannabinoids are universally helpful for pain.
The Bigger Picture
Having two independent systematic reviews reach the same conclusion in the same year strengthens the finding that evidence is insufficient. The osteoarthritis trial failure and the high rate of cognitive side effects are particularly important for the millions of older adults with OA who might consider cannabinoids.
What This Study Doesn't Tell Us
Extremely small combined sample size (203 patients). Short study durations. High risk of bias in all completed studies. No studies of herbal cannabis. Heterogeneous conditions and products limit comparison.
Questions This Raises
- ?Why did the osteoarthritis trial fail while others showed some benefit?
- ?Are the cognitive side effects dose-dependent, and would lower doses still provide pain relief?
- ?Would topical cannabinoid formulations avoid the systemic side effects?
Trust & Context
- Key Stat:
- Nearly 50% of patients reported dizziness, cognitive problems, or drowsiness
- Evidence Grade:
- Rigorous systematic review methodology, but the underlying evidence consists of only four small, short, high-bias trials.
- Study Age:
- Published in 2016. Additional trials may have been conducted since, but the evidence gap highlighted here was significant.
- Original Title:
- Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.
- Published In:
- Arthritis care & research, 68(5), 681-8 (2016)
- Authors:
- Fitzcharles, Mary-Ann(14), Ste-Marie, Peter A(2), Häuser, Winfried(13), Clauw, Daniel J, Jamal, Shahin, Karsh, Jacob, Landry, Tara, Leclercq, Sharon, Mcdougall, Jason J, Shir, Yoram, Shojania, Kam, Walsh, Zach
- Database ID:
- RTHC-01155
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids help with osteoarthritis?
The only osteoarthritis trial included in this review was terminated early because the treatment was not working, though studies in other rheumatic conditions showed some pain and sleep benefits.
What are the side effects of cannabinoids for pain?
Nearly half of patients in the reviewed trials experienced dizziness, cognitive problems, drowsiness, or nausea. No serious adverse events occurred during the short study periods.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-01155APA
Fitzcharles, Mary-Ann; Ste-Marie, Peter A; Häuser, Winfried; Clauw, Daniel J; Jamal, Shahin; Karsh, Jacob; Landry, Tara; Leclercq, Sharon; Mcdougall, Jason J; Shir, Yoram; Shojania, Kam; Walsh, Zach. (2016). Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.. Arthritis care & research, 68(5), 681-8. https://doi.org/10.1002/acr.22727
MLA
Fitzcharles, Mary-Ann, et al. "Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.." Arthritis care & research, 2016. https://doi.org/10.1002/acr.22727
RethinkTHC
RethinkTHC Research Database. "Efficacy, Tolerability, and Safety of Cannabinoid Treatments..." RTHC-01155. Retrieved from https://rethinkthc.com/research/fitzcharles-2016-efficacy-tolerability-and-safety-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.